Markets

Why Cyclerion Therapeutics Is Crashing Today

What happened

Shares of clinical-stage biotech Cyclerion Therapeutics (NASDAQ: CYCN) are down by an eye-popping 48% as of noon EDT Wednesday. The small-cap biotech's stock is crashing in response to a negative midstage trial result for its sickle cell disease candidate olinciguat.

Cyclerion didn't share any statistical details from the 70-patient study in today's press release. However, the company did note that the drug's activity did not support further internal clinical development. This event marks the second midstage trial failure for the biotech within a year.

A man getting punched in the face.

Image source: Getty Images.

So what

Sickle cell disease is a rare blood disorder with limited treatment options. Therefore, olinciguat stood a chance at becoming a rather healthy revenue generator for the company in the years ahead. That promising scenario, though, appears to be completely off with the table in the wake of these disappointing midstage results. Thus, it's easy to understand why investors are backing away from this prerevenue biotech stock today.

Now what

On the bright side, Cyclerion also announced positive clinical trial news for its early-stage drug candidate IW-6463 this morning. The drug is currently being evaluated as a possible treatment for age-related cognitive decline and neurodegenerative diseases. It reportedly exhibited blood-brain-barrier penetration, desired central nervous system exposure levels, and target engagement in an early-stage trial.

Cyclerion is thus planning to assess the drug across a broad range of central nervous system disorders, including mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. So there is a distinct possibility that the biotech's shares could eventually rebound from today's downturn.

10 stocks we like better than Cyclerion Therapeutics Inc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Cyclerion Therapeutics Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYCN

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More